636 results about "Ce Antibody" patented technology

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

Provided are antibodies against DLL3, antibody-drug conjugates comprising the antibodies, and methods of diagnosis and treatment of diseases associated with the expression of DLL3, such as cancer.

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.

The present invention relates to antibody-cytokine conjugates, wherein the cytokine is conjugated to the antibody via a cleavable linker. Conjugates according to the invention can be prepared by coupling a functionalized antibody Ab (F) x comprising x reactive moieties F, where x is an integer in the range of 1-10, with an immune cell-binding polypeptide comprising one or two reactive moieties Q, where the antibody is specific for tumor cells, and the immune cell-binding polypeptide is specific for immune cells, wherein the reaction forms a covalent bond between the functionalized antibody and the immune cell-binding polypeptide by reaction of Q with F. The invention further relates to antibody-cytokine conjugates obtainable by the method according to the invention and to medical uses thereof.

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

This disclosure pertains to compositions comprising an anti-FcRn antibody, M281. The compositions include the full, intact antibody and size variants thereof that not include two antibody heavy chains and to antibody light chains. Thus, a M281 pharmaceutical composition can include: an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:1, wherein the composition comprises a major protein component having a molecular weight of 140,000-145,000 Da and a minor protein component of molecular weight 118,000-120,000 Da.

The present application relates to an antibody specifically binding to an FOLR1 protein or an antigen-binding fragment thereof, and an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof. The present application also relates to a nucleic acid which codes the antibody specifically binding to the FOLR1 protein or the antigen-binding fragment thereof, a cell and pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof or the nucleic acid or the antibody-drug conjugate, and a use of the antibody or the antigen-binding fragment thereof or the antibody-drug conjugate in the prevention and / or treatment of FOLR1-mediated diseases.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat NGAL protein and application thereof. The monoclonal antibody combination of the application comprises monoclonal antibodies 1E2 and 2D6. The two antibodies have unique heavy chain and light chain variable region complementarity determining regions, and the amino acid sequences thereof have been defined in detail (SEQ ID NO. 1-12). The antibody combination can specifically recognize and efficiently bind to cat NGAL protein, and is suitable for developing a diagnostic tool with high sensitivity and high specificity. By constructing a double-antibody sandwich ELISA detection system, the minimum detection limit can reach 1 ng / mL, and good specificity and stability are shown.

The invention provides an anti-idiotypic nano antibody 28E1 of vitamin B12. A variable region sequence of the anti-idiotypic nano antibody 28E1 is shown as SEQ ID NO: 1. The antibody sequence of the anti-idiotype nano antibody 28E1 of the vitamin B12 is as shown in SEQ ID NO: 2. The antibody can specifically recognize the anti-VB12 monoclonal antibody 34C1 and inhibit the combination of the anti-VB12 monoclonal antibody 34C1 and VB12, and can be used for developing an immunodetection reagent based on a competition law principle.

The invention belongs to the technical field of biological detection, and particularly relates to a specific monoclonal antibody for AKK bacterium active protein P9, a detection kit and application of the specific monoclonal antibody. The antibody pair is 7G4 and 8B2, the amino acid sequence of a heavy chain variable region of the 7G4 is SEQ ID NO.2, and the amino acid sequence of a light chain variable region of the 7G4 is SEQ ID NO.4; the amino acid sequence of the 8B2 heavy chain variable region is SEQ ID NO.6, and the amino acid sequence of the 8B2 light chain variable region is SEQ ID NO.8. The antibody pair has strong specificity and high affinity, and can accurately recognize different antigen epitopes of the P9 protein. A colloidal gold detection and double-antibody sandwich ELISA detection system constructed based on the kit adapts to a complex matrix and various process treatment samples, is stable and reliable in detection, has qualitative and quantitative capabilities, can be used for scenes of P9 protein detection, fermentation monitoring, quality control and the like, and solves the problems of insufficient specificity, poor adaptability and the like in the prior art.

The invention provides an antibody for resisting CD27 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD27 antibody or an antigen binding fragment thereof, which can effectively bind to CD27 on the porcine B cell surface. The invention also provides an antibody drug conjugate and the like containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and has a good application prospect.

The present invention provides an antibody binding a human tumor-associated calcium signal sensor 2 (Trop-2) protein or fragments thereof, and use of the antibody or fragments thereof in preventing or treating diseases. The antibody or fragments thereof of the present invention can effectively bind to the human Trop-2 protein, and have internalization activity, and the internalization activity is enhanced after ADC drug labeling, and the in vivo efficacy and safety of a mouse model are not lower than those of a control antibody.

The invention relates to the technical field of biology, in particular to an anti-LIV-1 antibody or an antigen binding fragment thereof, an antibody drug conjugate and application thereof. Specifically, the LIV-1 antibody obtained by the invention has higher affinity and good endocytosis rate; the antibody drug conjugate containing the antibody has a remarkable cell killing effect and has a very strong tumor growth inhibition effect. The invention also relates to application of the antibody or the antigen binding fragment thereof and the antibody drug conjugate in preparation of drugs for treating cancers, and the antibody or the antigen binding fragment thereof and the antibody drug conjugate play an important role in treatment of human tumors.

The invention provides an antibody specifically targeting cardiac troponin I. The invention further provides a preparation method of the antibody. The invention further provides an antibody pair comprising the antibody and a kit. The invention further provides the use of these antibodies to detect the level of cardiac troponin I and to diagnose myocardial damage.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

The invention is a method and computer system for determining one or more parameters quantitatively characterising the interaction between an antigen and an antibody. The method comprises producing a test region carrying an antigen that produces a first luminescence spectrum, bringing into contact with the test region a sample solution comprising an antibody that forms a complex with the antigen and produces a second luminescence spectrum different from the first luminescence spectrum, recording an image (30) or images of the test region with a digital imaging device, producing a 2D histogram (40) from intensity values of the image (30), performing curve fitting on the points of the 2D histogram (40), and determining the one or more parameters by means of the fitted curve.

The present disclosure relates to anti-PTK7 antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the same, and use thereof in preparation of antibody-drug conjugates, and further relates to antibody-drug conjugates containing the antibodies or antigen-binding fragments thereof and preparation method and use thereof.

The present invention relates to a novel antibody targeting B7-H3 or an antigen-binding fragment thereof, a chimeric antigen receptor (CAR) comprising same, an immune cell comprising the CAR, and uses thereof. The CAR-T cells according to the present invention have low toxicity and excellent antitumor activity, and thus can be effectively used in immune cell treatment for cancer treatment.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

The present invention provides an anti-IL-23p19 antibody liquid pharmaceutical formulation comprising a) 150 mg / ml anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2; b) a polyol; and c) a surfactant. The high concentration formulations disclosed herein advantageously have storage stability and are suitable for subcutaneous administration.

The invention relates to an antibody or an antigen fragment of a targeted human CD7 and application of the antibody or the antigen fragment. The antibody and the CD7-CAR based on the antibody fragment have extremely strong affinity with a CD7 antigen molecule, and a blocking molecule containing the antibody can almost completely block the expression of the CD7 molecule on the cell surface without influencing the normal amplification of T cells, so that the self-killing of the CD7-CAR-T cells can be effectively avoided. The CD7-CAR-T cell constructed on the basis of the single-domain antibody of the targeted human source CD7 has a strong killing effect on a target cell.

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.

The present invention addresses the problem of providing a method for detecting a disease having a high risk of fracture.　Provided is an antibody specifically recognizing extracellular matrix protein 1 (ECM1), the antibody being characterized by: recognizing an epitope on ECM1 having the amino acid sequence represented by positions 20-540 of SEQ ID NO: 10, the epitope being located within positions 194-279 or 454-540 of SEQ ID NO: 10; or recognizing an epitope on a polypeptide having an amino acid sequence with at least 90% identity to the amino acid sequence represented by positions 20-540 of SEQ ID NO: 10, the epitope being located within positions corresponding to positions 194-279 or 454-540 of SEQ ID NO: 10.

The purpose of the present disclosure is to provide a molecule that shows different binding properties between a full capsid and an empty capsid of AAV. An antibody is provided that has a higher binding ability to an AAV empty capsid than to an AAV full capsid, under a condition (I) of pH 7.4 or a condition (II) of pH 3.0.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gB (507-734 aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the porcine pseudorabies virus gB protein in a sample, and has key significance on optimization of a porcine pseudorabies virus detection method, improvement of diagnosis accuracy and realization of effective prevention and control of epidemic situations.

The present invention relates to an antibody-conjugated drug containing a DHODH inhibitor, to an intermediate for preparing the antibody-conjugated drug, to a pharmaceutical composition containing the antibody-conjugated drug, and to the use of the antibody-conjugated drug for treating and / or preventing diseases.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 5F11 capable of broad-spectrum recognition of various antigens of AAV and an application of the monoclonal antibody 5F11. A heavy chain variable region and a light chain variable region of the monoclonal antibody 5F11 respectively comprise three complementary determining regions which correspond to SEQ ID NO.1-3 and SEQ ID NO.4-6. The monoclonal antibody 5F11 can specifically recognize AAV2, AAV8 and AAV9 antigens, and has the advantages of high sensitivity and broad spectrum. A double-antibody sandwich detection method constructed based on the antibody can detect three AAV antigens at the same time, and the detection cost is remarkably reduced. The clear variable region sequence lays a foundation for humanized transformation, recombinant expression and application in in-vitro detection platforms such as an ELISA kit and an immunochromatography test strip.